The potential role of kallistatin as a new biomarker in non-invasivediagnostics of non-alcoholic fatty liver disease with hypertension

Prof. O.Ya. Babak, prof. N.M. Zhelezniakova, as.prof. A.O. Rozhdestvenska

Kharkiv National Medical University

It is known that non-alcoholic fatty liver disease (NAFLD) is recognized as one of the most common diseases in the 21st century. A variant of the comorbidity is the combination of NAFLD with the hypertension (HT) increasing the risks of non-alcoholic steatosis progressing to non-alcoholic steatohepatitis (NASH). The disadvantages of a liver biopsy determine the relevance of searching for new non-invasive methods, that could confirm the diagnosis, determine the form, grade and severity of NAFLD. The review is devoted to the study of potential use of anti-inflammatory biomarker kallistatin for non-invasive diagnostics to assess fibrotic changes in liver and predict disease severity in non-alcoholic fatty liver patients with hypertension.

Key Words: kallistatin, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, biomarker, non-invasive diagnostics.

https://dx.doi.org/10.15407/internalmed2019.02.018

Download.PDF

For citing:

  1. Бабак, О.Я. Потенційна роль калістатину як нового біомаркера неінвазивної діагностики неалкогольної жирової хвороби печінки на тлі гіпертонічної хвороби / О.Я. Бабак, Н.М. Железнякова, А.О. Рождественська // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2019. – № 2. – С. 18-23. doi: 10.15407/internalmed2019.02.018.
  2. Babak OYa, Zhelezniakova NM, Rozhdestvenska AO. [The potential role of kallistatin as a new biomarker in non-invasive diagnostics of non-alcoholic fatty liver disease with hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2019;2:18-23. doi: 10.15407/internalmed2019.02.018.